Overdose from illicit fentanyl is the leading cause of death for working-age Americans. CounterX Therapeutics is committed to ending the fentanyl overdose epidemic and offering hope to individuals, families and communities devastated by this crisis. CounterX Therapeutics is developing CTRX-101, a once-monthly treatment that blocks fentanyl's lethal effects and prevents overdose. Supported by over $40M in NIH funding, we are positioned to address a critical public health crisis with a potential market of ~3.1M patients and peak-year sales of $4.6B.